Adrian Schwarzer
Overview
Explore the profile of Adrian Schwarzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaninetti C, Einweg M, Almann A, Schwarzer A
Br J Haematol
. 2025 Jan;
206(3):814.
PMID: 39810620
No abstract available.
2.
Fokken H, Waclawski J, Kattre N, Kloos A, Muller S, Ettinger M, et al.
Cytometry A
. 2023 Nov;
105(3):181-195.
PMID: 37984809
Multiparameter flow cytometry (MFC) has emerged as a standard method for quantifying measurable residual disease (MRD) in acute myeloid leukemia. However, the limited number of available channels on conventional flow...
3.
Bastone A, Dziadek V, John-Neek P, Mansel F, Fleischauer J, Agyeman-Duah E, et al.
Mol Ther Methods Clin Dev
. 2023 Sep;
30:515-533.
PMID: 37693949
Safety assessment in retroviral vector-mediated gene therapy remains challenging. In clinical trials for different blood and immune disorders, insertional mutagenesis led to myeloid and lymphoid leukemia. We previously developed the...
4.
Schwarzer A, Oliveira M, Kleppa M, Slattery S, Anantha A, Cooper A, et al.
Mol Cancer Ther
. 2023 Aug;
22(11):1290-1303.
PMID: 37643767
DLBCL are aggressive, rapidly proliferating tumors that critically depend on the ATF4-mediated integrated stress response (ISR) to adapt to stress caused by uncontrolled growth, such as hypoxia, amino acid deprivation,...
5.
Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, et al.
Haematologica
. 2023 Jul;
109(1):72-83.
PMID: 37470150
Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) without or...
6.
Stadler M, Venturini L, Bunting I, Dammann E, Weissinger E, Schwarzer A, et al.
Front Oncol
. 2022 Sep;
12:867356.
PMID: 36059667
Preemptive and therapeutic donor lymphocyte infusions (preDLI and tDLI) are widely used in relapsing and relapsed hematopoietic malignancies after allogeneic stem cell transplantation (alloSCT) to enhance the graft-versus-malignancy effect. However,...
7.
Tettero J, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al.
Hemasphere
. 2021 Dec;
6(1):e676.
PMID: 34964040
Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final...
8.
Kloos A, Mintzas K, Winckler L, Gabdoulline R, Alwie Y, Jyotsana N, et al.
Leukemia
. 2021 Nov;
35(12):3629.
PMID: 34728793
No abstract available.
9.
Schnoeder T, Schwarzer A, Jayavelu A, Hsu C, Kirkpatrick J, Dohner K, et al.
Blood
. 2021 Oct;
139(7):1080-1097.
PMID: 34695195
In an effort to identify novel drugs targeting fusion-oncogene-induced acute myeloid leukemia (AML), we performed high-resolution proteomic analysis. In AML1-ETO (AE)-driven AML, we uncovered a deregulation of phospholipase C (PLC)...
10.
Hassan J, Lieske A, Dorpmund N, Klatt D, Hoffmann D, Kleppa M, et al.
Int J Mol Sci
. 2021 Sep;
22(17).
PMID: 34502319
and are frequently upregulated in acute myeloid leukemia (AML), including those with MLL-rearrangement. Because of their pivotal role in hemostasis, HOXA9 and MEIS1 appear non-druggable. We, thus, interrogated gene expression...